Generic Aerospan HFA Availability

Aerospan HFA is a brand name of flunisolide, approved by the FDA in the following formulation(s):

AEROSPAN HFA (flunisolide - aerosol, metered;inhalation)

  • Manufacturer: MEDA PHARMS INC
    Approval date: January 27, 2006
    Strength(s): EQ 78MG BASE/INH [RLD]

Has a generic version of Aerospan HFA been approved?

No. There is currently no therapeutically equivalent version of Aerospan HFA available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aerospan HFA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Flunisolide aerosol formulations
    Patent 5,776,433
    Issued: July 7, 1998
    Inventor(s): Tzou; Tsi-Zong & Schultz; Robert K. & Ross; Danna L.
    Assignee(s): Minnesota Mining and Manufacturing Company
    Pharmaceutical aerosol formulations substantially free of chlorofluorocarbons and comprising a therapeutically effective amount of flunisolide in solution with ethanol and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof are used for the treatment of bronchial asthma. The formulation may be delivered by a metered dose inhaler with a canister that is inert to flunisolide.
    Patent expiration dates:
    • July 7, 2015
      ✓ 
      Drug product
  • Flunisolide aerosol formulations
    Patent 5,980,867
    Issued: November 9, 1999
    Inventor(s): Tzou; Tsi-Zong & Schultz; Robert K. & Ross; Danna L.
    Assignee(s): 3M Innovative Prperties Company
    Pharmaceutical aerosol formulations comprising flunisolide, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.
    Patent expiration dates:
    • December 20, 2013
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • August 28, 2016 - CLINICAL TRIAL STUDY RESULTS

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)